The global Gamma Knife market is projected to reach USD 875.0 million by 2036, up from USD 420.6 million in 2026, expanding at a CAGR of 7.6% from 2026 to 2036. Demand is being supported by the rising incidence of brain metastases, growing preference for non-invasive radiosurgery, and broader use of Gamma Knife technology in neurological and vascular conditions. In 2025, the American Society for Radiation Oncology (ASTRO) published clinical practice guidance on stereotactic radiosurgery for brain metastases, adding to the clinical evidence base supporting precision radiosurgery approaches.
Global Segment Leaders
- Brain Metastasis — 69.5% share: This is the leading disease indication because rising brain metastasis incidence and the preference for targeted radiosurgery are increasing treatment volumes.
- Head — 54.3% share: The head segment leads the anatomy category because Gamma Knife systems are primarily designed for precise treatment of intracranial targets.
- Hospitals — Leading end user: Hospitals remain the primary installation setting because Gamma Knife systems require substantial capital investment, radiation-shielded facilities, and multidisciplinary clinical teams.
- Oncology — Leading application: Oncology represents a major application area as Gamma Knife radiosurgery is increasingly used for brain metastases and other intracranial tumors.
The available market data provides explicit shares for the disease indication and anatomy segments, while the report identifies hospitals and oncology as leading categories without assigning percentage shares.
Country-Level Performance
The USA Gamma Knife market is projected to expand at a 7.4% CAGR through 2036. Growth is supported by demand for brain metastasis treatment, established comprehensive cancer centers, and expanding use of radiosurgery for functional neurosurgery applications.
South Korea is also expected to register a 7.4% CAGR. Oncology infrastructure investment, increasing demand for brain metastasis treatment, and rapid adoption of advanced medical technologies are supporting market expansion.
Japan is projected to grow at a 7.3% CAGR. Its established Gamma Knife installed base, advanced neurosurgical capabilities, and cancer-related treatment demand support continued procedure volumes and system upgrades.
The European Union is expected to record a 7.1% CAGR, supported by the expansion of comprehensive cancer centers and greater adoption of evidence-based radiosurgery for brain metastases. Academic medical centers are also supporting the development of functional neurosurgery applications.
The United Kingdom is projected to grow at a 7.0% CAGR, with NHS cancer-treatment modernization, rising brain metastasis treatment demand, and evidence-based technology adoption supporting Gamma Knife utilization.
Regional Context
The USA and South Korea form the fastest-growing group among the specifically profiled markets, both registering 7.4% CAGRs. Their growth reflects oncology infrastructure investment, demand for brain metastasis treatment, and expansion of radiosurgery programs. Japan follows closely at 7.3%, supported by its established treatment infrastructure and advanced neurosurgical capabilities.
The European Union and UK represent mature but steadily expanding markets, with CAGRs of 7.1% and 7.0%, respectively. Growth in these markets is linked to comprehensive cancer-center development, clinical evidence supporting stereotactic radiosurgery, and modernization of cancer treatment infrastructure. The broader report covers North America, Latin America, Europe, East Asia, South Asia and Pacific, and the Middle East and Africa, with analysis spanning more than 30 countries.
Competitive Landscape
The Gamma Knife market includes Elekta, Varian Medical Systems, Accuray Incorporated, Hitachi, Ltd., Huiheng Medical, Inc., Akesis, Inc., MASEP Medical Science Technology, American Radiosurgery Inc., Panacea Medical Technologies, and Nordion (Canada) Inc. Elekta maintains a particularly prominent position through the Leksell Gamma Knife platform, while Varian and Accuray address overlapping stereotactic radiosurgery applications through linear accelerator and robotic radiosurgery technologies.
Recent industry developments also highlight continued technology expansion. In July 2025, Elekta received U.S. FDA 510(k) clearance for its Gamma Knife radiosurgery system for adults with refractory, drug-resistant mesial temporal lobe epilepsy. In September 2025, Elekta announced that more than two million patients worldwide had received Leksell Gamma Knife radiosurgery, with the milestone treatment performed at Karolinska University Hospital in Sweden.
The latest generation of the platform, Elekta Esprit, incorporates advances in treatment planning, workflow, and precision while supporting frame-based and frameless treatment approaches.
Explore More Related Studies Published by FMI Research:
FMI Custom Research: Strategic Intelligence for Confident Decision-Making
In today’s rapidly evolving business environment, leadership teams need more than market data—they need clear, actionable intelligence tailored to their strategic objectives. FMI’s Custom Research solutions are designed around the specific business questions organizations need answered, enabling executives to evaluate growth opportunities, validate investments, assess competitive dynamics, and reduce uncertainty before making critical decisions. By combining deep industry expertise, primary research, and proprietary market intelligence, FMI delivers insights that help organizations move from assumptions to evidence-based strategies with greater speed and confidence.
Key Executive Benefits
- Decision-Ready Insights: Research tailored to your specific business challenges, growth plans, and investment priorities.
- Reduced Strategic Risk: Validate market opportunities, customer demand, and competitive positioning before committing resources.
- Market Entry Confidence: Assess opportunity size, regulatory barriers, channel dynamics, and competitive landscapes with precision.
- Competitive Advantage: Gain proprietary intelligence unavailable through syndicated reports or internal datasets.
- Faster Growth Decisions: Accelerate expansion, product development, portfolio optimization, and investment planning.
- Primary Market Validation: Access real-world customer, buyer, and stakeholder insights that support high-confidence decision-making.
- Global Industry Expertise: Powered by 100+ analysts, 20,000+ published reports, and 1.6 million+ hours of research experience.
- Proven Track Record: Over 7,000 market-entry engagements completed across six regions and 14 industry sectors with strong client retention.
Business Impact
FMI helps organizations transform market complexity into strategic clarity, enabling leadership teams to identify growth opportunities faster, optimize resource allocation, strengthen competitive positioning, and make high-stakes business decisions with confidence.
To explore how FMI Custom Research can support your strategic priorities, please connect with our team at – sales@futuremarketinsights.com
About Future Market Insights (FMI)
Future Market Insights is a leading provider of market intelligence, consulting services, and syndicated research reports. FMI delivers actionable insights across food and beverage, healthcare, consumer goods, biotechnology, chemicals, industrial products, and emerging technologies, helping organizations identify growth opportunities and make informed strategic decisions in evolving global markets.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
Why FMI: https://www.futuremarketinsights.com/why-fmi
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
